Wiendl H - Search Results

1

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis.

Fleck AK, Schuppan D, Wiendl H, Klotz L. Fleck AK, et al. Among authors: wiendl h. Int J Mol Sci. 2017 Jul 14;18(7):1526. doi: 10.3390/ijms18071526. Int J Mol Sci. 2017. PMID: 28708108 Free PMC article. Review.

2

Janus head: the dual role of HLA-G in CNS immunity.

Huang YH, Airas L, Schwab N, Wiendl H. Huang YH, et al. Among authors: wiendl h. Cell Mol Life Sci. 2011 Feb;68(3):407-16. doi: 10.1007/s00018-010-0582-5. Epub 2010 Nov 18. Cell Mol Life Sci. 2011. PMID: 21086150 Free PMC article. Review.

3

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Klotz L, Meuth SG, Wiendl H. Klotz L, et al. Among authors: wiendl h. Clin Immunol. 2012 Jan;142(1):25-30. doi: 10.1016/j.clim.2011.04.006. Epub 2011 Apr 15. Clin Immunol. 2012. PMID: 21550857 Review.

4

Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ.

Hucke S, Floßdorf J, Grützke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Brüstle O, Kurts C, Klockgether T, Neumann H, Prinz M, Wiendl H, Knolle P, Klotz L. Hucke S, et al. Among authors: wiendl h. Brain. 2012 May;135(Pt 5):1586-605. doi: 10.1093/brain/aws058. Epub 2012 Mar 24. Brain. 2012. PMID: 22447120

5

Monoclonal antibodies in neuroinflammatory diseases.

Klotz L, Wiendl H. Klotz L, et al. Among authors: wiendl h. Expert Opin Biol Ther. 2013 Jun;13(6):831-46. doi: 10.1517/14712598.2013.767329. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23521026 Review.

6

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Wiendl H, Gross CC. Wiendl H, et al. Nat Rev Neurol. 2013 Jul;9(7):394-404. doi: 10.1038/nrneurol.2013.95. Epub 2013 Jun 4. Nat Rev Neurol. 2013. PMID: 23732529 Review.

7

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

Zipp F, Gold R, Wiendl H. Zipp F, et al. Among authors: wiendl h. JAMA Neurol. 2013 Dec;70(12):1569-74. doi: 10.1001/jamaneurol.2013.4391. JAMA Neurol. 2013. PMID: 24145957 Review.

8

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Schwab N, Schneider-Hohendorf T, Wiendl H. Schwab N, et al. Among authors: wiendl h. Int Immunol. 2015 Jan;27(1):47-53. doi: 10.1093/intimm/dxu096. Epub 2014 Oct 17. Int Immunol. 2015. PMID: 25326459 Review.

9

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, Bopp T, Jonuleit H, Jolivel V, Zipp F, Witsch E. Luessi F, et al. Among authors: wiendl h. Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2. Mult Scler. 2015. PMID: 25732840

10

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Grützke B, Hucke S, Gross CC, Herold MV, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L. Grützke B, et al. Among authors: wiendl h. Ann Clin Transl Neurol. 2015 Feb;2(2):119-30. doi: 10.1002/acn3.155. Epub 2015 Jan 16. Ann Clin Transl Neurol. 2015. PMID: 25750917 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

755 results

Search Page

Filters